(HKSE:6855),(NasdaqGM:AAPG), 76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment lines for a broader patient population ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 […]

(HKSE:6855),(NasdaqGM:AAPG), Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival) ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group

(HKSE:6855),(NasdaqGM:AAPG), By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectively High-risk IKZF1plus patients showed 90% molecular response rate Low-intensity chemotherapy combination achieved deep responses with favorable safety profile ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE

ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment GlobeNewswire December 09, 2025 76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP GlobeNewswire December 09, 2025 Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% GlobeNewswire December 09, 2025 By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were

(Other OTC:RTGN),(OTC US:RTGN), APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer,

RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO Zwerling expected to guide the Company to its commercial launch GlobeNewswire December 09, 2025 APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic

Edelson Lechtzin LLP, a national class action law firm based in suburban Philadelphia, is investigating potential violations of the federal securities laws involving CoreWeave, Inc. (NASDAQ: CRWV), resulting from allegations of providing potentially misleading business information to the investing public. https://mma.prnewswire.com/media/2457789/logo2_Logo.jpg If you have information that could assist in the CoreWeave Investigation or if you

Vancouver, British Columbia–(Newsfile Corp. – December 8, 2025) – Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) (“Sage Potash” or the “Company”) announces a non-brokered private placement of up to 35,000,000 units of the Company (“Units”) at a price of $0.20 per Unit for gross proceeds of up to $7 million (the “Offering”). Each Unit will